Trials / Completed
CompletedNCT04563767
Feasibility - Infinitome
Feasibility of Utilizing the Infinitome Program to Evaluate Abnormal Large Scale Brain Networks in Alzheimer's Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4 (actual)
- Sponsor
- HealthPartners Institute · Academic / Other
- Sex
- All
- Age
- 40 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The Infinitome Program from Omniscient has the ability to identify abnormal brain networks or connectomes using resting state functional MRI (rs-fMRI). This technology, which visualizes brain networks in three dimensions, was originally developed to ensure neurosurgeons avoid inadvertently lesioning cognitively eloquent brain regions during surgical operations. The potential of Infinitome in identifying connectome dysfunction for neurodegenerative diseases such as Alzheimer's disease has yet to be explored. This diagnostic technique may play a critical role for identifying disease brain networks that may benefit from targeted interventions in clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Infinitome | Added sequence of rs-fMRI. |
Timeline
- Start date
- 2020-09-15
- Primary completion
- 2020-10-13
- Completion
- 2020-10-13
- First posted
- 2020-09-24
- Last updated
- 2021-02-17
- Results posted
- 2021-02-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04563767. Inclusion in this directory is not an endorsement.